Alumis (ALMS) Stock Crashes Over 50% Following Lupus Trial Disappointment

Key Takeaways

• Shares of Alumis plummeted approximately 56% following the announcement that its Phase 2b LUMUS study of envudeucitinib failed to achieve primary and secondary goals in the broader lupus patient cohort.
• The study included 408 participants but did not reach its primary goal of measuring disease activity improvement at the 48-week mark.
• Patients identified as IFNGS-high in a prespecified analysis demonstrated significant positive outcomes, though this subset was underrepresented in the overall study population.
• The biotech firm continues to target a Q4 2026 submission for a New Drug Application covering envudeucitinib in plaque psoriasis, supported by encouraging Phase 3 data.
• Management plans to meet with regulatory authorities to discuss launching a Phase 3 trial specifically targeting lupus patients with high interferon gene signatures.

Alumis shares experienced a devastating collapse on Tuesday, falling approximately 56% after the biotechnology company disclosed that its Phase 2b LUMUS clinical trial evaluating envudeucitinib failed to demonstrate efficacy in individuals suffering from moderate-to-severe systemic lupus erythematosus (SLE).

At one point during the trading session, the stock plummeted as much as 57.86%. Such a dramatic single-session decline represents a significant blow for any biotechnology firm.

Alumis Inc., ALMS

The clinical study recruited 408 participants and evaluated disease activity utilizing the British Isles Lupus Assessment Group-based Composite Lupus Assessment, abbreviated as BICLA, at the 48-week timepoint. This served as the trial’s primary measure of success. Unfortunately, it was not achieved.

Additional secondary measures in the complete patient population also failed to reach statistical significance.

However, the company highlighted one encouraging finding. A predetermined subset of patients exhibiting elevated interferon gene signatures, designated as IFNGS-high, demonstrated substantial clinical improvement on both the primary measure and crucial secondary outcomes.

Patients classified as IFNGS-high represent the majority of moderate-to-severe SLE diagnoses. The challenge was that this group was unexpectedly underrepresented in the current study, which negatively impacted the overall trial outcomes.

According to Alumis, envudeucitinib demonstrated favorable tolerability across the study duration. No unexpected safety concerns emerged during the trial.

Pharmacodynamic analysis also verified substantial dose-dependent modulation of the interferon signaling pathway, with the maximum dose of 40mg administered twice daily producing the greatest suppression effect.

Alumis’ Strategic Path Forward

Management indicated plans to engage in discussions with regulatory agencies regarding the development of a Phase 3 clinical program specifically designed for the IFNGS-high patient segment.

Alumis emphasized that no targeted oral treatment options currently exist for SLE, which the company views as compelling justification to continue advancing development efforts in this therapeutic area.

The psoriasis development program continues to advance as planned. Alumis maintains its timeline to file a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis during the fourth quarter of 2026.

This regulatory submission builds upon favorable results from the company’s Phase 3 ONWARD clinical program evaluating the drug in plaque psoriasis.

Understanding Alumis’ Broader Context

Envudeucitinib functions as an oral allosteric inhibitor targeting tyrosine kinase 2, commonly referred to as TYK2. The therapeutic mechanism involves modulating immune signaling pathways regulated by IL-23, IL-17, and Type I interferon.

The compound’s mechanism of action remains consistent whether treating lupus or psoriasis, which explains why the positive IFNGS-high subset results continue to generate interest among investors and industry analysts monitoring the development pipeline.

Prior to Tuesday’s selloff, the company maintained a market capitalization of approximately $2.99 billion. Year-to-date, the stock had delivered returns exceeding 123% before the trial announcement.

Average daily share volume typically hovered around 1.29 million shares before the clinical results became public.

Technical sentiment indicators had assigned a Hold rating to the stock before the announcement emerged.

The post Alumis (ALMS) Stock Crashes Over 50% Following Lupus Trial Disappointment appeared first on Blockonomi.